Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | March 28, 2017 |
| End Date: | April 1, 2021 |
| Contact: | Bethany Wendel, RN |
| Email: | Bethany.Wendel@cshs.org |
| Phone: | 310-967-4339 |
The purpose of this study is to examine the usefulness of matching patients to targeted
therapy by analyzing a tumor sample taken at diagnosis and testing it against 50
cancer-associated genes. Targeted therapy is a highly personalized, newer approach to cancer
treatment that aims to more precisely identify and attack cancer cells, in an effort to do
less damage to normal cells.
therapy by analyzing a tumor sample taken at diagnosis and testing it against 50
cancer-associated genes. Targeted therapy is a highly personalized, newer approach to cancer
treatment that aims to more precisely identify and attack cancer cells, in an effort to do
less damage to normal cells.
Targeted therapy in this study can be either off label-use of a U.S. Food and Drug
Administration (FDA) approved drug or a clinical trial that includes investigational drugs.
Matched targeted therapy outcomes will be compared to the outcomes of patients who were not
matched to a treatment.
In order to find a matched treatment, a patient's sample will undergo a test known as a "gene
chip algorithm." This is will be done by having a sample of a patient's tumor analyzed at a
Cedars-Sinai Medical Center (CSMC) laboratory that specializes in molecular profiling.
Molecular profiling is a process used to study a tumor's genetic characteristics. DNA will be
taken from the tumor sample and will be screened for "actionable genes." These genes are
called actionable because mutations (structural changes) in these genes have FDA-approved
matched therapies or are eligible for current clinical studies.
Administration (FDA) approved drug or a clinical trial that includes investigational drugs.
Matched targeted therapy outcomes will be compared to the outcomes of patients who were not
matched to a treatment.
In order to find a matched treatment, a patient's sample will undergo a test known as a "gene
chip algorithm." This is will be done by having a sample of a patient's tumor analyzed at a
Cedars-Sinai Medical Center (CSMC) laboratory that specializes in molecular profiling.
Molecular profiling is a process used to study a tumor's genetic characteristics. DNA will be
taken from the tumor sample and will be screened for "actionable genes." These genes are
called actionable because mutations (structural changes) in these genes have FDA-approved
matched therapies or are eligible for current clinical studies.
Inclusion Criteria:
- Advances and metastatic solid tumors who have failed standard treatments known to
improve survival
- Female and male adults age 18 and older.
- PS 0-2
- Acceptable hematological, renal, or liver function
- Patients planning to undergo a systemic treatment
- Written informed consent obtained from subject and ability for subject to comply with
the requirements of the study.
Exclusion Criteria:
- Significant comorbidities that could interfere with the study (compliance and visits)
We found this trial at
1
site
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Monica Mita, MD
Phone: 310-967-4339
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
